Trump said overnight that the US would soon introduce a 'major tariff' on pharmaceuticals to force firms to relocate medicine production to America.

Ohio and Indiana are suing the makers of a popular heartburn medication, saying the drug company concealed cancer risks and ...

KEY TAKEAWAYS The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U ...

Key Takeaways Shares of several drugmakers fell Wednesday as the threat of tariffs on the industry loomed.President Donald ...

The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his ...

Following a second measles-related death in Texas, Robert F. | The HHS secretary called out the measles vaccines as "the most ...

In a jobs market marred by a hiring slowdown, Staffline (STAF) appears to be bucking the trend. Unlike its larger peers, the Aim-listed blue-collar recruiter grew revenue, underlying operating profits ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.